The Supreme Court has agreed to hear arguments this December concerning Purdue Pharma’s bankruptcy claims. Until then, the high court has blocked a $6 Billion settlement fund for cases related to opioid abuse. Purdue is “confident in the legality of [our] nearly universally supported Plan of Reorganization, and optimistic the […]
Other Pharmaceuticals
18 posts
By Buck Daniel May 1, 2014 – The judge managing the diabetes drug MDL has filed several orders shaping the next steps in the litigation. On Oct. 15, 2013, Judge Lloyd D. George filed an order scheduling a hearing on transferring several new cases to drugs Januvia, Byetta and Victoza […]
By Buck Daniel March 20, 2013 – Two years ago, the Supreme Court severely limited the conditions under which consumers could sue generic drug manufacturers. The Pliva v. Mensing decision stated that generic manufacturers do not have control over a drug’s warning label content due to FDA regulations; and therefore, […]
Posted by Buck Daniel February 25, 2013 – On February 23rd, Affymax and Takeda instituted a recall of OMONTYS following serious adverse reactions, including life threatening and fatal events. Omontys is used to treat anemia associated with chronic kidney disease for patients on dialysis. Anemia, in which the body is […]
Posted by Buck Daniel September 6, 2012 – Bayer recently informed its investors of the potential costs that will be necessary to settle outstanding lawsuits regarding its birth control medication, Yaz. The company admits it faces no fewer than 12,325 lawsuits regarding the higher risks associated with its product. Nearly […]
June 12, 2012 – A ten-year study recently concluded that thiazolidinedione drugs, such as Avandia and Actos, may increase the risk of macular edema, a serious eye condition that can lead to blindness. It noted that the incidence of macular edema in studied patients on these drugs was more than […]
June 1, 2012 – American Association for Justice Trial Magazine June 2012 Drugs & Devices: How Big Pharma Puts Patients at Risk “Bad Actos” by Howard L. Nations and John M. Restaino “The safety of Actos, an oral diabetes drug that increases the body’s sensitivity to insulin, has been increasingly […]
By Amber Stanford May 26, 2012 – The FDA has recently recognized a new study released in the issue May 17, 2012 of the New England Journal of Medicine that reports a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a […]
By Cindy L. Nations December 22, 2011 – Three days before Christmas, the FDA issued a warning about a new concentration of liquid acetaminaphen for infants. The pain and fever medication has long been available in 80 mg/0.8 mL and 80 mg/mL strength. The drug is now also available in […]
By Moe Taheri December 9, 2011 – Yaz and Yasmin may cause a significantly higher risk of blood clots compared to older birth control pills. These recent medical findings were reviewed yesterday by an FDA advisory committee that is evaluating the risks and benefits of Yaz and Yasmin. An FDA […]
By Moe Taheri November 29, 2011 – Last week Merck & Co. agreed to pay $321.6 million in criminal fines to resolve investigations into Merck’s illegal and fraudulent activities related to its pain killer Vioxx. Federal and state prosecutors alleged that Merck committed Medicare and Medicaid fraud and engaged in […]
Posted November 18, 2011 by M. Miller The F.D.A. is revoking its approval of the drug Avastin for breast cancer. This comes after concluding that it “has not been shown to be safe and effective for that use.” Roche, the maker of Avastin, states it will remain an approved treatment […]
By Moe Taheri November 17, 2011 – The AP (11/16) reported, “Amid pressure from activists, Johnson & Johnson said Wednesday that it is continuing efforts to remove traces of two harmful chemicals from its baby products around the world. An international coalition of consumer and environmental groups has been pressing […]
By Cindy L. Nations November 14, 2011 – Judge John F. Keenan recently re-scheduled the trial for two bellwether cases in the Fosamax MDL. The trials are now scheduled for September 2012 in the Southern District of New York. A bellwether trial is commonly used in mass torts cases where […]
September 12, 2011 – The FDA reports that, for the Medtronic Model 8637 SynchroMed II Implantable Infusion Pump, there is a Class I Recall due to the potential for reduced battery performance that can lead to the sudden loss of therapy and the return of underlying symptoms and/or therapy withdrawal […]
Posted March 26, 2010 by Cindy L. Nations A status conference has been scheduled for April 14, 2010 at 9:00 a.m. before Judge David R. Herndon in the U.S. District Court, Southern District of Illinois. The conference is regarding the “Yasmin and Yaz (Drospirenone) Marketing, Sales Practice and Products Liability […]
Posted March 26, 2010 by Cindy L. Nations A Pretrial Conference is scheduled for Thursday, April 1, 2010 at 1:30 p.m. before Judge Donald M. Middlebrooks in the U.S. District Court, Southern District of Florida, West Palm Beach Division. This is in the Trasylol multi-district litigation consisting of nation-wide lawsuits […]
By Chris Sbrusch October 23, 2009 – On October 20, 2009, the US District Court for the Northern District of Ohio conducted a status conference with lead counsel for Ortho Evra Products Liability Litigation MDL Docket number 1742. The previous dates (Doc. No. 377) regarding designation of cases regarding post […]